PATENT COOPERATION TREATY

PCT

REC'D	0	2	MAR	2001
-------	---	---	-----	------

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

A 1: 11 - 11 5: 0	r		
Applicant's or agent's file reference 8511-025-228	FOR FURTHER ACT	Prelimina	
International application No.	International filing date	(day/month/year)	Priority date (day/month/year)
PCT/US99/08079	15 APRIL 1999		NONE
International Patent Classification (IPC) IPC(7): GO1N 55/55; A61K 58/00; A	or national classification and US Cl.:	and IPC 435/7.23; 530/324;	514/2, 12
Applicant NORTHWEST BIOTHERAPEUTICS	, INC.		
2. This REPORT consists of a This report is also accomp	total of sheets. eanied by ANNEXES, i.e. basis for this report and on 607 of the Administrat	cant according to , sheets of the descortainin	ription, claims and/or drawings which have g rectifications made before this Authority.
3. This report contains indication	s relating to the following	ng items:	
I X Basis of the repor	t		
II Priority			
III Non-establishmen	t of report with regard	to novelty, inventi	ve step or industrial applicability
IV X Lack of unity of i	nvention		
V X Reasoned statement citations and explan	under Article 35(2) with ations supporting such st	regard to novelty,	inventive step or industrial applicability,
VI Certain documents c	ited		
VII Certain defects in th	e international applicatio		
VIII Certain observations	on the international app	lication	
Date of submission of the demand		Date of completion	of this report
08 NOVEMBER 2000		04 FEBRUARY	2001
Name and mailing address of the IPEA/U	/l ·	uthorized officer	0 -0
Commissioner of Patents and Trademas Box PCT Washington, D.C. 20231	rks	Jennifer Hunt	Brid ger
Facsimile No. (703) 505-3250	7	Telephone No. (7	03) 308-0196



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/08079

L I	Basis 1	f the report		
1. Wi	th regan	to the elements of the intern	national application:*	
x	•	nternational application as		
x	.	lescription:		
[A	J page:	s <u>1-52</u>		, as originally filed
		NONE		_ , filed with the demand
	page	NONE NONE	, filed with the letter of	
<u></u>	l +ba a	laims:		
X		53-56		
			, as amended (together with any s	, as originally filed
		NONE	, as amonated (to gottles with any s	
			, filed with the letter of	
	·			
X		rawings:	•	
		1-15		- •
		NONE NONE		_ , filed with the demand
	pages	NONE	, filed with the letter of	
x	the se	quence listing part of the	lescription:	
لتتا				as originally filed
	pages	NONE		, filed with the demand
	pages	NONE	, filed with the letter of	
The	the lar	ents were available or furnishinguage of a translation funguage of publication of the guage of the translation furn	unless otherwise indicated under this item. hed to this Authority in the following language rnished for the purposes of international search (under Rule 48.3(b)). hished for the purposes of international preliminary examples.	nder Rule 23.1(b)).
3. Wi	th regar	d to any nucleotide and/or	r amino acid sequence disclosed in the international	application, the international
pre	liminar	y examination was carried	out on the basis of the sequence listing:	,
X	contai	ned in the international a	pplication in printed form.	
			onal application in computer readable form.	
님			Authority in written form.	
\sqsubseteq			Authority in computer readable form.	
	The strinterna	atement that the subsequentional application as filed	tly furnished written sequence listing does not go be has been furnished.	yond the disclosure in the
	The sta been fi	tement that the information	recorded in computer readable form is identical to the	writen sequence listing has
4. X	The ar	mendments have resulted	in the cancellation of:	
	X	the description, pages	NONE	
		the claims, Nos.	NONE	
		the drawings, sheets/fig	NONE	
5.			ome of the amendments had not been made it at	
~ LJ	bevon	d the disclosure as filed as i	ome of) the amendments had not been made, since they ndicated in the Supplemental Box (Rule 70.2(c)).**	nave been considered to go
in in	acement	sheets which have been furni	ished to the receiving Office in response to an invitation un are not annexed to this report since they do not contain	nder Article 14 are referred to in amendments (Rules 70.16
		ment sheet containing such	amendments must be referred to under item 1 and an	nexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US99/08079

IV. Lack funity finvention
1. In response to the invitation to restrict or pay additional fees the applicant has:
restricted the claims.
X paid additional fees.
paid additional fees under protest.
neither restricted nor paid additional fees.
2. This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68. not to invite the applicant to restrict or pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
complied with.
x not complied with for the following reasons:
This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 15.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.
Group I, claim(s)1-12 and 23, drawn to a method of detection of metastatic potential. Group II, claim(s) 13-22, and 24-29 drawn to a product, fil-4, a process of making and process of using to treat, inhibit, or prevent secondary metastasis. The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:
The inventions in group I are drawn to a method of detecting the expression of flt-4 and subsequent determination of the metastatic potential of a cell.
The inventions in group II are drawn to inhibition of flt-4 for the purpose of treating, inhibiting, or preventing secondary metastasis.
The detection of fit-4 and the inhibition of fit-4 are distinctly different processes, having different reactants, method steps, and outcomes and therefor do not share a specific technical feature.
į
4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:
X all parts.
the parts relating to claims Nos



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

statement			
Novelty (N)	Claims	1-29	Y.
	Claims	NONE	N
Inventive Step (IS)	Claims	1-29	Y 1
,	Claims	NONE	NO.
Industrial Applicability (IA)	Claims	1-29	
moustat Applicatinty (1A)	Claims	NONE	YI
laims 1-29 meet the criteria set out in PC prelation between flt-4 detection and the presponding treatments, compositions, or s	netastatic poten screening metho	tial or occupance of metastasis in prostation	fairly suggest the carcinoma, or the
ONE NEW CITATIONS			
	·		